Imunon Inc (IMNN) - Total Liabilities
Based on the latest financial reports, Imunon Inc (IMNN) has total liabilities worth $4.66 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Imunon Inc - Total Liabilities Trend (1996–2025)
This chart illustrates how Imunon Inc's total liabilities have evolved over time, based on quarterly financial data. See Imunon Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Imunon Inc Competitors by Total Liabilities
The table below lists competitors of Imunon Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UET United Electronic Technology AG
XETRA:CFC
|
Germany | €49.88 Million |
|
Kibo Energy PLC
JSE:KBO
|
South Africa | ZAC3.83 Million |
|
Augros Cosmetic Packaging SA
PA:AUGR
|
France | €12.18 Million |
|
T4F Entretenimento S.A
SA:SHOW3
|
Brazil | R$292.05 Million |
|
Ho Hup Construction Company
KLSE:5169
|
Malaysia | RM298.27 Million |
|
E Media Holdings Ltd
JSE:EMH
|
South Africa | ZAC1.80 Billion |
|
Morella Corporation Ltd
AU:1MC
|
Australia | AU$6.85 Million |
|
Grolleau SAS
PA:ALGRO
|
France | €20.22 Million |
Liability Composition Analysis (1996–2025)
This chart breaks down Imunon Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Imunon Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Imunon Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Imunon Inc (1996–2025)
The table below shows the annual total liabilities of Imunon Inc from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.23 Million | -4.51% |
| 2024-12-31 | $5.47 Million | -35.84% |
| 2023-12-31 | $8.53 Million | -41.76% |
| 2022-12-31 | $14.65 Million | -19.74% |
| 2021-12-31 | $18.25 Million | -3.52% |
| 2020-12-31 | $18.92 Million | -20.25% |
| 2019-12-31 | $23.72 Million | -8.75% |
| 2018-12-31 | $25.99 Million | +24.91% |
| 2017-12-31 | $20.81 Million | -13.74% |
| 2016-12-31 | $24.12 Million | -15.78% |
| 2015-12-31 | $28.64 Million | -15.43% |
| 2014-12-31 | $33.87 Million | +139.41% |
| 2013-12-31 | $14.15 Million | +5.60% |
| 2012-12-31 | $13.40 Million | +107.52% |
| 2011-12-31 | $6.46 Million | -9.08% |
| 2010-12-31 | $7.10 Million | +48.88% |
| 2009-12-31 | $4.77 Million | +20.39% |
| 2008-12-31 | $3.96 Million | -52.77% |
| 2007-12-31 | $8.39 Million | -62.10% |
| 2006-12-31 | $22.13 Million | +77.27% |
| 2005-12-31 | $12.48 Million | +145.70% |
| 2004-12-31 | $5.08 Million | +414.88% |
| 2003-12-31 | $986.84K | +27.34% |
| 2002-12-31 | $774.96K | +169.42% |
| 2001-12-31 | $287.64K | -26.51% |
| 2000-12-31 | $391.39K | -34.77% |
| 1999-12-31 | $600.00K | -72.50% |
| 1998-12-31 | $2.18 Million | -33.56% |
| 1997-12-31 | $3.28 Million | +27.99% |
| 1996-12-31 | $2.57 Million | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more